目的 探討喹硫平聯(lián)合氟哌啶醇治療對(duì)精神分裂癥患者激越行為的影響。方法 采用回顧性研究方法，2015年1月-2016年9月選擇在新鄉(xiāng)醫(yī)學(xué)院第二附屬醫(yī)院診治的精神分裂癥患者115例，根據(jù)治療方法的不同分為觀察組60例與對(duì)照組55例，對(duì)照組給予喹硫平治療，觀察組給予喹硫平聯(lián)合氟哌啶醇治療，比較兩組的治療效果、不良反應(yīng)、血脂改變及激越行為評(píng)分情況。結(jié)果 觀察組的總有效率96.7%（58/60）高于對(duì)照組87.3%（48/55），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組的不良反應(yīng)發(fā)生率為21.7%（13/60），對(duì)照組為21.8%（12/55），且兩組的不良反應(yīng)都為輕中度。治療后兩組血清低密度脂蛋白膽固醇（LDL-C）、總膽固醇（TC）、三酰甘油（TG）、高密度脂蛋白膽固醇（HDL-C）含量對(duì)比無(wú)差異。治療后觀察組與對(duì)照組的激越行為評(píng)分分別為（8.14±6.33）分和（13.01±6.10）分，顯著低于治療前的（22.22±5.33）分和（22.09±4.82）分（P<0.05），同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 喹硫平聯(lián)合氟哌啶醇治療精神分裂癥患者能有效控制激越行為，提高治療效果，且不會(huì)增加不良反應(yīng)的發(fā)生，也不會(huì)影響患者的血脂水平，有很好的應(yīng)用價(jià)值。

Objective To investigate the effects of quetiapine combined with haloperidol on the aggressive behavior of schizophrenic patients. Methods Used a retrospective study, From January 2015 to September 2016, 115 patients with aggressive behavior of schizophrenic patients in our hospital for treatment were selected. All the patients were divided into the observation group of 70 patients and control group of 45 patients accorded to the different methods of drugs, the control group was treated with quetiapinet, the observation group was quetiapine combined with haloperidol. Compare the therapeutic effect of two groups. Results The total effective rate of observation group was 96.7% (58/60) compared to 87.3% (48/55) of the control group (P<0.05). The adverse reaction rate of the observation group was 21.7% (13/60), and the control group was 21.8% (12/55), and the adverse reactions in both groups were mild to moderate. After treatment, the content of serum HDL-C, TC and TG in the observation group werelower than that of the control group (P<0.05), and there were no difference in the comparison of the content of HDL-C in the two groups. After treatment, the agitation score of the observation group and the control group were (8.14±6.33) points and (13.01±6.10) points, which was significantly lower than those before treatment of (22.22±5.33) points and (22.09±4.82) points (P<0.05). The observation group was lower than the control group (P<0.05). Conclusion The quetiapine combined with haloperidol in the treatment of schizophrenia can effectively control the agitation behavior, improve the treatment effect, and will not increase the occurrence of adverse reactions, and will not affect the level of blood lipids of patients. It has a very good application value.